DBV Technologies Shares Drop 3.43% Despite a 182% Surge Over the Year
DBV Technologies fell by 3.43% this Wednesday, trading at 3.72 euros, in a pullback that contrasts with the recent bullish trend. The biotech company, specializing in food allergies, has still shown a growth of 182% over the year and 22% over the last three months, indicating a sustained interest in the stock.
Current Trading Session
Today, DBV Technologies' stock is trading at 3.72 euros, down from yesterday's close of 3.85 euros. This decline comes after the stock had increased by 5.5% over the past seven days. Technically, the price is in the upper part of the Bollinger Bands, at 87% of the range between the lower bound (3.28 euros) and the upper bound (3.79 euros), signaling a potential overbought zone. This positioning suggests that the stock has appreciated quickly and that profit-taking may explain today's correction. Additionally, the RSI at 60 remains in neutral territory without reaching the overheating zone, which moderates the short-term bearish signal. The CAC 40, meanwhile, is down 0.52% at 8,284 points, while the SBF 120 is down 0.47%. In the healthcare sector, performances are mixed: Sanofi is up 1%, while UCB is down 0.30%. In the US, AbbVie is up 1.84% and Johnson & Johnson is up 0.90% during the session, whereas Eli Lilly is down 0.76%. Thus, the sector environment does not provide a clear direction for biotechs in mid-April.
Medium and Long-Term Trajectory
Beyond today's session, it is the medium and long-term trajectory of DBV Technologies that captures attention. With a gain of 182% over twelve months and 22% over three months, the stock has experienced significant revaluation. The current price of 3.72 euros is well above the 200-day moving average, which is at 2.68 euros, a gap of nearly one euro. The 50-day moving average (3.66 euros) has also been crossed upwards in recent weeks, confirming an established bullish trend. The beta of 0.60 indicates a volatility lower than that of the overall Paris market, which can be explained by the specific profile of the biotech, less correlated with major macroeconomic cycles. However, the monthly volatility of 22.26% remains high in absolute terms, characteristic of stocks in this segment. The first identified support is at 3.37 euros, which could provide a base if the current consolidation continues.
